{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:02:59Z","timestamp":1781276579381,"version":"3.54.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sociedad Espa\u00f1ola de Farmacia Cl\u00ednica, Familiar y Comunitaria"},{"name":"Sociedad Espa\u00f1ola de Medicos de Atenci\u00f3n Primaria"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the outcomes of chronic kidney disease (CKD) screening in community pharmacies through creatinine measurement and glomerular filtration rate (GFR) estimation in patients meeting specific risk criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter observational study. People who entered participating pharmacies for any reason and met the inclusion criterion of not having a CKD diagnosis were invited to participate in the study. If they agreed, the pharmacist conducted a point-of-care blood creatinine test, and the GFR was calculated using the CKD\u2013EPI formula. Those with a positive CKD indicator (&amp;lt;45\u00a0ml\/min\/1.73\u00a0m2) were referred to their general practitioner (GP) for evaluation. People with a GFR\u2009&amp;gt;\u200960\u00a0ml\/min\/1.73\u00a0m2 were not considered to have CKD. Those with a GFR between 45 and 60\u00a0ml\/min\/1.73\u00a0m2 were asked to return for reassessment 1\u00a0month later. Those with a GFR\u200945 &amp;lt;\u2009ml\/min\/1.73\u00a0m2 were then considered CKD-positive and referred to the GP. All the data were recorded by the pharmacist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>One hundred and forty-one community pharmacies from 40 provinces of Spain enrolled 2116 patients. In the first analysis, 1428 (67.5%) were negative, 165 (7.8%) were positive, and 523 (24.7%) needed a second analysis. In the second analysis, 164 (7.8%) were negative, 243 (11.5%) were positive, and 116 (5.5%) did not reattend. In summary, by intention to treat, 1592 (75.2%) were negative and 408 (19.3%) tested positive and were referred to their GP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of CKD detection in community pharmacies are in line with screening in other healthcare settings, confirming they could be a reliable resource in future population-screening strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riaf088","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:23:15Z","timestamp":1758540195000},"page":"235-242","source":"Crossref","is-referenced-by-count":0,"title":["Screening for chronic kidney disease in community pharmacy: Crierfac project"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7145-5772","authenticated-orcid":false,"given":"Jos\u00e9","family":"Espejo-Guerrero","sequence":"first","affiliation":[{"name":"Community Pharmacist in Adra , Natalio Rivas Street, 35, 04770 Adra, Almer\u00eda ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9142-0569","authenticated-orcid":false,"given":"Luis","family":"Salar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Community Pharmacist in Valencia , Jos\u00e9 Aguilar, 27, 46022 Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-3189","authenticated-orcid":false,"given":"Eduardo","family":"Satu\u00e9-de-Velasco","sequence":"additional","affiliation":[{"name":"Community Pharmacist in Maella , Vias San Francisco Street, 30, 50710 Maella, Zaragoza ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-0505","authenticated-orcid":false,"given":"Lourdes","family":"Mart\u00ednez-Berganza-Asensio","sequence":"additional","affiliation":[{"name":"General Practitioner in Ensanche de Vallecas Health Center , Cincovillas Street, 5, 28051 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-8623","authenticated-orcid":false,"given":"Noem\u00ed","family":"P\u00e9rez-Le\u00f3n","sequence":"additional","affiliation":[{"name":"General Practitioner Gran Sol Primary Care Center , Badalona, Dr Bassols Avenue, 112, 08914 Badalona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"2026061210414509400_ref1","volume-title":"Global Kidney Health Atlas [Internet]","author":"International Society of Nephrology"},{"key":"2026061210414509400_ref2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"KDIGO CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026061210414509400_ref3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.nefro.2021.07.010","article-title":"Information and consensus document for the detection and management of chronic kidney disease","volume":"42","author":"Garc\u00eda-Maset","year":"2022","journal-title":"Nefrologia."},{"key":"2026061210414509400_ref4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2026061210414509400_ref5","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"2026061210414509400_ref6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1053\/j.ajkd.2013.12.012","article-title":"Cost-effectiveness of primary screening for CKD: a systematic review","volume":"63","author":"Komenda","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026061210414509400_ref7","volume-title":"Statistics on Registered Pharmacists and Community Pharmacies 2023 [Internet]","author":"General Council of Official Colleges of Pharmacists","year":"2024"},{"key":"2026061210414509400_ref8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1715163520902495","article-title":"Community pharmacist identification of chronic kidney disease using point-of-care technology: a pilot study","volume":"153","author":"Donovan","year":"2020","journal-title":"Can Pharm J (Ott)"},{"key":"2026061210414509400_ref9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1715163515618421","article-title":"Community pharmacist targeted screening for chronic kidney disease","volume":"149","author":"Al Hamarneh","year":"2016","journal-title":"Can Pharm J (Ott)"},{"key":"2026061210414509400_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2054358120922617","article-title":"Community pharmacy-based eGFR screening for early detection of CKD in high-risk patients","volume":"7","author":"Papastergiou","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"2026061210414509400_ref11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/nep.13247","article-title":"Evaluation of a chronic kidney disease risk assessment service in community pharmacies","volume":"24","author":"Gheewala","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"2026061210414509400_ref12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nephro.2016.06.006","article-title":"Implication du pharmacien d\u2019officine dans le parcours de soins de la maladie r\u00e9nale chronique","volume":"13","author":"Belaiche","year":"2017","journal-title":"N\u00e9phrol Th\u00e9rapeutique"},{"key":"2026061210414509400_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2026061210414509400_ref14","doi-asserted-by":"publisher","first-page":"e0122433","DOI":"10.1371\/journal.pone.0122433","article-title":"Evaluation of the Nova StatSensor\u00ae Xpress(TM) creatinine point-of-care handheld analyzer","volume":"10","author":"Kosack","year":"2015","journal-title":"PLoS One"},{"key":"2026061210414509400_ref15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.33620\/FC.2173-9218","article-title":"Evaluation of the blood creatinine meter Nova StatSensor Xpress\u00ae in a community pharmacy","volume":"12","author":"Espejo","year":"2020","journal-title":"Farm Comunitarios"},{"key":"2026061210414509400_ref16","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/diagnostics14141542","article-title":"Community point-of-care testing in diagnosing and managing chronic kidney disease","volume":"14","author":"Gama","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026061210414509400_ref17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/17151635241291854","article-title":"Medication therapy problems detected at community pharmacy INR checks","volume":"158","author":"Nagge","year":"2024","journal-title":"Can Pharm J (Ott)"},{"key":"2026061210414509400_ref18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.clinmicnews.2017.09.004","article-title":"Point-of-care testing for group a streptococcus infection and influenza","volume":"39","author":"Woo","year":"2017","journal-title":"Clin Microbiol Newsl"},{"key":"2026061210414509400_ref19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33620\/FC.2173-9218.(2023).27","article-title":"May measurement month 2019: screening analysis in Spanish community pharmacies and detection of masked hypertension","volume":"15","author":"Mera-Gallego","year":"2023","journal-title":"Farm Comunitarios"},{"key":"2026061210414509400_ref20","doi-asserted-by":"publisher","first-page":"e0278648","DOI":"10.1371\/journal.pone.0278648","article-title":"Pharmaceutical care program for patients with chronic kidney disease in the community pharmacy: detection of nephrotoxic drugs and dose adjustment. Viability study","volume":"17","author":"Escrib\u00e1-Mart\u00ed","year":"2022","journal-title":"PLoS One"},{"key":"2026061210414509400_ref21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2296-14-96","article-title":"Effectiveness of a drug dosing service provided by community pharmacists in polymedicated elderly patients with renal impairment\u2014a comparative study","volume":"14","author":"Via-Sosa","year":"2013","journal-title":"BMC Fam Pract"},{"key":"2026061210414509400_ref22","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3892\/etm.2017.4389","article-title":"StatSensor-i point-of-care creatinine analyzer may identify patients at high risk of contrast-induced nephropathy","volume":"13","author":"Inoue","year":"2017","journal-title":"Exp Ther Med"},{"key":"2026061210414509400_ref23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.26502\/fccm.92920229","article-title":"Point-of-care capillary blood creatinine: a prospective study in cardiology and nephrology outpatients","volume":"5","author":"Vilaine","year":"2021","journal-title":"Cardiol Cardiovasc Med"},{"key":"2026061210414509400_ref24","volume-title":"SEFAC e_XPERT: Digital Platform for Patient Management in Community Pharmacy [Internet]","author":"Sociedad Espa\u00f1ola de Farmacia Cl\u00ednica Familiar y Comunitaria (SEFAC)"},{"key":"2026061210414509400_ref25","volume-title":"Fundamentals of Design and Statistics. Unit 6. Parameter Estimation: Confidence Interval and Sample Size","author":"D\u00f2menech","year":"2018","edition":"19th"},{"key":"2026061210414509400_ref26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.medcli.2020.03.005","article-title":"Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: results of the IBERICAN study","volume":"156","author":"Llisterri","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"2026061210414509400_ref27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026061210414509400_ref28","volume-title":"Nova Max Pro: Detection of Kidney Disease outside the Hospital \u2013 a New Easy-to-Use Tool to Detect Early-Stage Kidney Disease [Internet]","author":"Nova Biomedical"},{"key":"2026061210414509400_ref29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.33620\/FC.2173-9218.(2024).12","article-title":"Screening for chronic kidney disease in the community pharmacy. CRIERFAC study: description of the methodology","volume":"16","author":"Salar","year":"2024","journal-title":"Farm Comunitarios"},{"key":"2026061210414509400_ref30","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Otero Gonz\u00e1lez","year":"2010","journal-title":"Nefrolog\u00eda (Madr)"},{"key":"2026061210414509400_ref31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.nefro.2018.04.004","article-title":"Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"2026061210414509400_ref32","doi-asserted-by":"publisher","first-page":"e079110","DOI":"10.1136\/bmjopen-2023-079110","article-title":"Impact of a pharmacy-led screening and intervention in people at risk of or living with chronic kidney disease in a primary care setting: a cluster randomised trial protocol","volume":"13","author":"Tesfaye","year":"2023","journal-title":"BMJ Open"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/3\/235\/64640405\/riaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/3\/235\/64640405\/riaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:41:56Z","timestamp":1781275316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/34\/3\/235\/8283676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,11]]},"published-print":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaf088","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,10,11]]}}}